Ticker

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements

SeaStar Medical Holding Corporation (NASDAQ: ICU - Get Free Report) saw a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 286,335 shares, a growth of 85.5% from the January 29th total of 154,400 shares. Approximately 7.6% of the company's shares are sold short. Based on

SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences:

SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025.

Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE…